VEG108838
Laufzeit: 01.01.2008 - 31.12.2011
Kurzfassung
A randomized, multicenter, Phase III study comparing the combination of Pazopanib and Lapatinib versus Lapatinib monotherapy in Patients with ErbB2 over-expressing inflammatory Breast cancer
Laufzeit: 01.01.2008 - 31.12.2011
A randomized, multicenter, Phase III study comparing the combination of Pazopanib and Lapatinib versus Lapatinib monotherapy in Patients with ErbB2 over-expressing inflammatory Breast cancer
